Michael J Overman

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. doi request reprint Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials
    M J Overman
    Department of Gastrointestinal Medical Oncology
    Ann Oncol 27:1068-74. 2016
  2. pmc Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Unit 426, 1515 Holcombe Blvd, Unit 421, Houston, TX, 77030, USA
    BMC Cancer 16:668. 2016
  3. pmc Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 8:e65144. 2013
  4. pmc Improving the AJCC/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg 257:1072-8. 2013
  5. doi request reprint Use of research biopsies in clinical trials: are risks and benefits adequately discussed?
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 31:17-22. 2013
  6. pmc A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 19:1439-45. 2012
  7. doi request reprint Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77005, USA
    Clin Colorectal Cancer 7:338-42. 2008
  8. doi request reprint Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:5374-82. 2010
  9. doi request reprint Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:2549-55. 2010
  10. doi request reprint Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 426, Houston, TX 77030, USA
    Cancer 116:1446-53. 2010

Detail Information

Publications66

  1. doi request reprint Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials
    M J Overman
    Department of Gastrointestinal Medical Oncology
    Ann Oncol 27:1068-74. 2016
    ..Incorporation of multiple enrichment biomarkers into prospective clinical trials is an active area of investigation, but the factors that determine clinical trial enrollment following a molecular prescreening program have not been assessed...
  2. pmc Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Unit 426, 1515 Holcombe Blvd, Unit 421, Houston, TX, 77030, USA
    BMC Cancer 16:668. 2016
    ..This study explored the novel use and potential prognostic utility of a 92-gene cancer classifier in ampullary adenocarcinomas...
  3. pmc Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 8:e65144. 2013
    ..We sought to molecularly classify ampullary adenocarcinomas in comparison to known adenocarcinomas of the pancreas, bile duct, and duodenum by gene expression analysis...
  4. pmc Improving the AJCC/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg 257:1072-8. 2013
    ....
  5. doi request reprint Use of research biopsies in clinical trials: are risks and benefits adequately discussed?
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 31:17-22. 2013
    ..Although the incorporation of research biopsies into clinical trials is increasing, limited information is available about how study protocols and informed consents integrate and describe their use...
  6. pmc A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 19:1439-45. 2012
    ..Because of its rarity, adenocarcinoma of the small intestine is frequently compared to adenocarcinoma of the colon, although the validity of this comparison is not known...
  7. doi request reprint Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77005, USA
    Clin Colorectal Cancer 7:338-42. 2008
    ..Such trimodality therapy can result in durable palliation of symptoms and long-term survival for patients with recurrent CRC involving the duodenum and pancreas, even when other metastases are present...
  8. doi request reprint Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:5374-82. 2010
    ..The objective of the current study was to evaluate the impact of the number of positive and negative lymph nodes on survival after curative resection...
  9. doi request reprint Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 28:2549-55. 2010
    ..We sought to explore the relationship between oxaliplatin induced hepatic sinusoidal injury, increases in spleen size, and the subsequent development of thrombocytopenia...
  10. doi request reprint Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 426, Houston, TX 77030, USA
    Cancer 116:1446-53. 2010
    ..The objective of the current study was to evaluate the efficacy and tolerability of a weekly formulation of DCF...
  11. ncbi request reprint EGFR-targeted therapies in colorectal cancer
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Dis Colon Rectum 50:1259-70. 2007
    ..The current status of epidermal growth factor receptor-targeted therapeutic agents is reviewed, with emphasis on their role in the management of colorectal cancer...
  12. pmc Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine
    M J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Br J Cancer 102:144-50. 2010
    ..To better understand the molecular abnormalities in small bowel adenocarcinoma (SBA), we characterised a number of candidate oncogenic pathways and the immunophenotype of this rare cancer...
  13. doi request reprint Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston Texas, 1515 Holcombe Blvd, Houston, TX, 77030, USA
    Invest New Drugs 26:445-54. 2008
    ..0194 to 0.197 1/h/kg. The recommended phase II doses for TAS-102 are 100 mg/m(2)/day on schedule A and 160 mg/m(2)/day on schedule B. Future development of TAS-102 should focus upon multiple daily dosing schedules...
  14. doi request reprint Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:2038-45. 2008
    ..The objective of this retrospective study was to determine whether the addition of a platinum compound to 5-FU provided any benefit in the treatment of patients with metastatic SBA...
  15. doi request reprint Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors
    Michael J Overman
    University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    Cancer Invest 26:794-9. 2008
    ..No responses were noted, but nine patients demonstrated prolonged stable disease in this heavily pretreated 5-FU refractory population...
  16. ncbi request reprint Worsening of thrombotic thromboctyopenic purpura symptoms associated with desmopressin administration
    Michael Overman
    MD Anderson Cancer Centre, Unit 10, 1515 Holcombe Blvd, Houston, Texas 77030, USA
    Thromb Haemost 92:886-7. 2004
  17. doi request reprint Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Acta Oncol 49:474-9. 2010
    ..We undertook a retrospective analysis to evaluate the benefit of adjuvant therapy in a clearly defined patient population with curatively resected small bowel adenocarcinoma...
  18. doi request reprint Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Unit 426, Houston, TX 77030, USA
    J Clin Oncol 27:2598-603. 2009
    ..We conducted a phase II trial to evaluate the benefit of capecitabine in combination with oxaliplatin (CAPOX) in patients with advanced adenocarcinoma of small bowel or ampullary origin...
  19. pmc Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases
    Andreas Andreou
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg 256:642-50. 2012
    ..We hypothesized that metachronous colorectal liver metastases (CLM) have different biology after failure of oxaliplatin (FOLFOX) compared to 5-fluorouracil (5-FU) or no chemotherapy for adjuvant treatment of colorectal cancer (CRC)...
  20. pmc Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
    Antoine Brouquet
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:4484-92. 2011
    ..Patient outcomes following resection of colorectal liver metastases (CLM) after second-line chemotherapy regimen is unknown...
  21. doi request reprint Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases
    Dan G Blazer
    Department of Surgical Oncology, Gastrointestinal Medical Oncology, and Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 26:5344-51. 2008
    ..The secondary goal of the study was to identify the clinical predictors of pathologic response...
  22. pmc Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy
    Scott Kopetz
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 27:3677-83. 2009
    ....
  23. doi request reprint Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy?
    Antoine Brouquet
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    J Am Coll Surg 210:934-41. 2010
    ..An increasing number of patients with synchronous colorectal liver metastases (CLM) are candidates for resection. The optimal treatment sequence in these patients has not been defined...
  24. pmc High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome
    Antoine Brouquet
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
    J Clin Oncol 29:1083-90. 2011
    ..The impact of complete resection in this well-selected group is controversial...
  25. pmc Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance
    Scott Kopetz
    University of Texas MD Anderson Cancer Center Lyndon B Johnson Hospital, Harris County Hospital District, Houston, TX, USA
    J Clin Oncol 28:453-9. 2010
    ....
  26. pmc Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma
    Maryam Zenali
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030
    Hum Pathol 44:2792-8. 2013
    ..Patients with DAC had less frequent nodal metastasis and better prognosis than those with PDA. There was no significant difference in prognosis between DAC and AA. ..
  27. ncbi request reprint Role of biologic therapy in the treatment of unresectable appendiceal epithelial neoplasms (AEN)
    Cathy Eng
    University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 30:628. 2012
    ..VEGF expression reportedly is a poor prognostic indicator in AEN pts. The purpose of this analysis is to determine the benefit of BT in chemotherapy naïve suboptimal candidates for CRS...
  28. ncbi request reprint Improving the AJCC/TNM staging for adenocarcinomas of the appendix: The prognostic impact of histologic grade
    Michael J Overman
    University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 30:402. 2012
    ....
  29. ncbi request reprint Prognostic and predictive effect of COX-2 expression in appendiceal adenocarcinomas
    Kanwal Pratap Singh Raghav
    University of Texas M D Anderson Cancer Center, Houston, TX The University of Texas Houston, Houston, TX
    J Clin Oncol 30:526. 2012
    ..However, its role in this setting has never been well studied. The purpose of our study was to investigate COX-2 expression in AAs and to evaluate its prognostic and predictive significance...
  30. doi request reprint Fatal diffuse alveolar damage associated with oxaliplatin administration
    Jack Watkins
    Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, USA
    Clin Colorectal Cancer 10:198-202. 2011
    ..Other cases of pulmonary toxicity associated with oxaliplatin use are presented and the proposed pathophysiology of this rare occurrence is discussed...
  31. ncbi request reprint Systematic survey of therapeutic trials for metastatic colorectal cancer
    Zhiyu Chen
    Fudan University, Shanghai, China University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 30:523. 2012
    ..JCO) demonstrated a very low utilization of novel therapies and minimal biomarker integration. The extent of change of mCRC clinical trials 5 years later is unknown...
  32. doi request reprint Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study
    Pat Gulhati
    Hematology Oncology Fellowship Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer . 2016
    ..Herein, the authors conducted a phase 2 trial to evaluate the benefit of adding bevacizumab to CAPOX...
  33. pmc Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 6:12809-21. 2015
    ..5 vs. 9.8 months, p = 0.001), which was confirmed in multivariable analysis. [Corrected]..
  34. doi request reprint Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience
    Jamie F Shapiro
    Division of Pharmacy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 1402, USA
    Cancer 116:316-22. 2010
    ..A retrospective analysis was conducted to determine the benefit of modern systemic chemotherapy in patients with disseminated appendiceal neoplasm who were not considered optimal candidates for cytoreductive surgery...
  35. doi request reprint Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury
    Julian H Slade
    Department of Pharmacy, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Colorectal Cancer 8:225-30. 2009
    ..The literature on hepatic sinusoidal injury after oxaliplatin is reviewed and the proposed pathophysiology is discussed...
  36. ncbi request reprint CT imaging interval after complete cytoreductive surgery/hyperthermic intraperitoneal chemotherapy (HIPEC) for well-differentiated adenocarcinoma of the appendix (WDAA)
    Karen A Beaty
    University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 30:434. 2012
    ..Minimal evidence-based data exists to direct recommendations regarding optimal imaging intervals in patients with WDAA...
  37. ncbi request reprint Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
    David S Hong
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer Discov 6:1352-1365. 2016
    ..7 months. BRAFV600E circulating cell-free DNA (cfDNA) trends correlated with radiographic changes, and acquired mutations from cfDNA in genes reactivating MAPK signaling were observed at progression...
  38. doi request reprint Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Oncotarget . 2016
    ..Hypermethylation of promoter CpG islands (CIMP) has been strongly implicated in chemotherapy resistance and is implicated in the pathogenesis of a subset of colorectal cancers (CRCs) termed CIMP-high...
  39. doi request reprint Intrathoracic Chemoperfusion Decreases Recurrences in Patients with Full-Thickness Diaphragm Involvement with Mucinous Appendiceal Adenocarcinoma
    Travis E Grotz
    Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 23:2914-9. 2016
    ..The clinical significance of diaphragmatic invasion and the optimum management to prevent transmission of disease from abdomen to chest is largely unknown...
  40. ncbi request reprint Exploratory analysis of adjuvant chemotherapy effects after preoperative chemoradiotherapy and radical resection for rectal cancer
    In Ja Park
    University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 30:557. 2012
    ..The aim of study was to explore the relationship between CXRT response and adjuvant CTx for patients with rectal cancer treated by CXRT and radical resection...
  41. ncbi request reprint Can we identify patients with cancer at high risk for cachexia? A prospective study in pancreatic cancer (PC)
    David R Fogelman
    University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 30:219. 2012
    ..Symptoms such as pain, nausea and anorexia may predict weight loss. Inflammatory cytokines are also associated with cachexia. We evaluated the ability of each to predict weight loss in newly diagnosed PC patients...
  42. pmc Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes
    Kanwal Raghav
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 11:e0154985. 2016
    ..This study describes clinicopathological features, outcomes and challenges in caring for AYA-CUP patients...
  43. ncbi request reprint The role of partial splenic embolization (PSE) in the management of chemotherapy-induced thrombocytopenia
    Aki Ohinata
    University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 30:569. 2012
    ..The impact of refinement in technique with limited volume embolization (50-70%) of the spleen upon morbidity and mortality has not been well studied...
  44. pmc Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction
    Jay Chouhan
    Department of Internal Medicine, The University of Texas Health Sciences Center, Houston, Texas
    Cancer Med 5:239-47. 2016
    ..026) independently predicted for longer OS. Concurrent treatment with systemic chemotherapy and TPN for persistent MSBO results in low efficacy and a high morbidity and mortality, and thus should not represent a standard approach. ..
  45. doi request reprint BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Mol Cancer Ther 15:1397-404. 2016
    ..A higher percentage of mutant BRAF(V600) in cfDNA corresponded with shorter OS and in patients receiving BRAF/MEK inhibitors also with shorter TTF. Mol Cancer Ther; 15(6); 1397-404. ©2016 AACR. ..
  46. pmc Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer
    Van Morris
    Department of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX
    Clin Colorectal Cancer 13:164-71. 2014
    ..However, the outcomes with standard chemotherapy over sequential lines of therapy in a large cohort of patients with BRAF-mutant tumors have not been described...
  47. doi request reprint Goblet cell carcinoid tumor, mixed goblet cell carcinoid-adenocarcinoma, and adenocarcinoma of the appendix: comparison of clinicopathologic features and prognosis
    Melissa W Taggart
    From the Departments of Pathology Drs Taggart, Abraham, and Rashid, Medical Oncology Dr Overman, and Surgical Oncology Dr Mansfield, MD Anderson Cancer Center, University of Texas, Houston
    Arch Pathol Lab Med 139:782-90. 2015
    ..However, GCTs can have mixed morphologic patterns, with variable amount of adenocarcinoma...
  48. pmc Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations
    Prasanth Ganesan
    Corresponding Author Filip Janku, Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, FC8 2018, Box 0455, Houston, Texas 77030
    Mol Cancer Ther 12:2857-63. 2013
    ..PIK3CA mutations are associated with simultaneous KRAS mutations, possibly accounting for therapeutic resistance...
  49. pmc Palliative venting gastrostomy in patients with malignant bowel obstruction and ascites
    Colette Shaw
    Section of Interventional Radiology, Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 20:497-505. 2013
    ..We report our clinical experience in cases of MBO and ascites that were known to be technically difficult and at increased risk for complications after PDGT placement...
  50. doi request reprint Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway
    Scott Kopetz
    Department of Gastrointestinal Medical Oncology, M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 426, Houston, TX 77030, USA
    J Clin Oncol 26:2000-5. 2008
    ..It is unclear to what extent aspects of this "Critical Path Initiative" have been adopted in trial designs in metastatic colorectal cancer...
  51. ncbi request reprint Use of bevacizumab to reduce the rate of oxaliplatin-induced thrombocytopenia and splenomegaly
    Michael J Overman
    University of Texas M D Anderson Cancer Center, Houston, TX University of Texas Medical School at Houston, Houston, TX Hospital Sírio Libanês, Sao Paulo, Brazil Department of Diagnostic Imaging, University of Texas M D Anderson Cancer Center, Houston, TX Hospital Sírio Libanês and Instituto do Cancer do Estado de São Paulo, Universidade de Sao Paulo, Sao Paulo, Brazil
    J Clin Oncol 30:564. 2012
    ..4% vs 3.4%, P <0.01) was seen in the bevacizumab arm. Evidence suggests that bevacizumab may protect against HSI, though the clinical impact of this has not been well examined...
  52. ncbi request reprint Clinicopathologic characteristics of patients with appendiceal adenocarcinoma (AA) and intra-thoracic metastasis
    Joshua S Hill
    University of Texas M D Anderson Cancer Center, Houston, TX
    J Clin Oncol 30:427. 2012
    ..Distant metastases, including those to the lung or pleura, are considered rare. We investigated the clinical characteristics and survival in patients with AA and intra-thoracic metastases...
  53. doi request reprint Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity
    Randa Tao
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA Department of Radiation Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA Electronic address
    Radiother Oncol . 2017
    ..To evaluate outcomes and toxicity in patients treated with hyperfractionated pelvic reirradiation for recurrent rectal cancer...
  54. pmc Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?
    David R Fogelman
    M D Anderson Cancer Center, 1515 Holcombe Drive, Houston, TX, 77030, USA
    J Cachexia Sarcopenia Muscle 5:307-13. 2014
    ..IGF-1 plays a role in the growth of multiple tumor types, including pancreatic cancer. IGF-1 also serves as a growth factor for muscle. The impact of therapeutic targeting of IGF-1 on muscle mass is unknown...
  55. doi request reprint Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial
    Ying Guo
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1414, Houston, TX, 77030, USA
    Support Care Cancer 22:1223-31. 2014
    ..We tested whether alpha-lipoic acid (ALA) could decrease the severity of peripheral neuropathy symptoms in patients undergoing platinum-based chemotherapy...
  56. pmc High-level microsatellite instability in appendiceal carcinomas
    Melissa W Taggart
    Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 37:1192-200. 2013
    ....
  57. doi request reprint Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary
    Christopher R Garrett
    Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Clin Colorectal Cancer 11:191-4. 2012
    ..The purpose of this study was to determine the outcome of patients with colorectal cancer metastatic to the ovary and the impact of surgical oophorectomy on the outcome...
  58. doi request reprint MET amplification in metastatic colorectal cancer: An acquired response to EGFR inhibition, not a de novo phenomenon
    Kanwal Raghav
    Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget . 2016
    ..Validation of MET amplification rate in mCRC is critical to this field...
  59. pmc From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology
    Kanwal Pratap Singh Raghav
    Kanwal Pratap Singh Raghav, Sminil Mahajan, James C Yao, Brian P Hobbs, Donald A Berry, Alda Tam, Waun K Hong, Lee M Ellis, and Michael J Overman, The University of Texas MD Anderson Cancer Center, Houston, TX Rebecca D Pentz, Emory School of Medicine, Atlanta, GA and James Abbruzzese, Duke Cancer Institute, Durham, NC
    J Clin Oncol 33:3583-90. 2015
    ..However, limited information is available on how this initiative effected transparency and selective reporting of clinical trial data...
  60. pmc Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer
    Scott Kopetz
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0018 4, Houston, TX 77030, USA
    BMC Cancer 14:660. 2014
    ..We retrospectively evaluated the activation of Src and FAK in hepatic metastases of colorectal cancer and correlated these findings with the clinical outcomes of patients treated with oxaliplatin...
  61. doi request reprint Small bowel adenocarcinomas--existing evidence and evolving paradigms
    Kanwal Raghav
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Centre, Unit 426, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Nat Rev Clin Oncol 10:534-44. 2013
    ....
  62. ncbi request reprint Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality
    Jason W Denbo
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1484, Houston, TX, 77030, USA
    J Gastrointest Surg 20:1975-1985. 2016
    ..The impact of preoperative chemoradiation on postoperative morbidity and mortality of patients with pancreatic adenocarcinoma remains controversial...
  63. doi request reprint Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection
    Guillaume Passot
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX
    Surgery . 2016
    ..RAS mutations are associated with limited overall survival after resection of colorectal liver metastases. Our aim was to determine criteria for considering hepatectomy for patients with RAS mutant colorectal liver metastases...
  64. pmc ABO non-O type as a risk factor for thrombosis in patients with pancreatic cancer
    Donghui Li
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer Med 4:1651-8. 2015
    ..A better understanding of the risk factors for TE in PC may help to identify patients who are most likely to benefit from prophylactic anticoagulation therapy...
  65. pmc Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression
    Arun Satelli
    Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Clin Cancer Res 21:899-906. 2015
    ..This study aimed to detect cell-surface vimentin (CSV) on the surface of epithelial-mesenchymal transitioned (EMT) circulating tumor cells (CTC) from blood of patients with epithelial cancers...
  66. doi request reprint Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness
    Seth Politano
    University of Texas Health Science Center, Houston, TX, USA
    Clin Colorectal Cancer 7:55-9. 2008
    ..However, it is unclear which patient, disease, and treatment characteristics are associated with the utilization of a second-line regimen...